Marking an important milestone since its first approval in May 2001, Gleevec� has become the first oncology drug to be validated as an effective and generally well-tolerated edicine that targets a specific cause of a cancer....
Read More...
[Source: Society News]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment